Publikationen

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M; Swiss Group for Clinical Cancer Research (SAKK).
Lung Cancer. 2012 Dec;78(3):239-44

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Cathomas R, Rothermund C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S, Swiss Group for Clinical Cancer Research SAKK.
Clin Cancer Res. 2012 Nov 1;18(21):6049-57

Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double-blind study of Denosumab and zoledronic acid.
Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K.
Cancer. 2012 Sep 5

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.
Schoenewolf NL, Dummer R, Mihic-Probst D, Moch H, Simcock M, Ochsenbein A, Gillessen S, Schraml P, von Moos R; Swiss Group for Clincial Cancer Research (SAKK).
Case Rep Oncol. 2012 May;5(2):280-9

Predective value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus Bevacizumab in the trial SAKK 50/07.
Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R.
Oncol Rep. 2012 Aug;28(2):654-8

Denosumab: first data and ongoing studies on the prevention of bone metastases.
von Moos R, Skacel T.
Recent Results Cancer Res. 2012;192:187-96

Update Melanoma – Wieder mehr Licht im Dunkeln.
Mark M, von Moos R.
Info@Onkologie. 2012(05):28-31

Update zur Behandlung des metastasierten malignen Melanoms: Beginn einer neuen Ära mit zielgerichteter Therapie?
von Moos R, Cathomas R, Mark M, Hitz F.
Praxis. 2012;101(22):1423-1429

Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with Gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).
Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D’Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Strupp R.
Eur J Cancer, 2012 Feb;48(3):377-84

A poled analysis of sequential therapies with sorafenib and Sunitinib in metastatic renal cell carcinoma.
Stenner F, Chastonay R, Liewen H, Haile SR, Cathomas R, Rothermundt C, Siciliano RD, Stoll S, Knuth A, Buchler T, Porta C, Renner C, Samaras P.
Oncology. 2012;82(6):333-40

Diagnosis and treatment of diffuse large B-cell lymphoma.
Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, Meier O, Yeow K, Renner C.
Swiss Med Wkly. 2012 Jan 30;142

Lung cancer screening: current evidence and recommendations.
Mark M, Brutsche M, Gautschi O.
MEMO 2012;5:144-148

Lungenkrebs-Screening: Pro und Contra.
Mark M, Brutsche M, Gautschi O.
Schweizer Krebsbulletin 2012;2:107-109

Fatal Pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.
Mark M, Thürlimann B.
Med Oncol. 2012:Volume 29(3):1477-78

Intravascular lymphoma mimicking cerebral stroke: report oft wo cases.
Hundsberger T, Cogliatti S, Kleger GR, Fretz C, Gähler A, Anliker M, Fournier JY, von Moos R, Tettenborn B, Driessen C.
Case Rep Neurol. 2011 Sep;3(3):278-83

Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers.
Huober J, Baumann M, Rochlitz C, Aebi S, Güth U, von Moos R, Müller A, von Rohr L, Widmer I, Thürlimann B.
Oncology. 2011;81(3-4):160-6

Efficacy and safety of bevaiczumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Pivot X, Schneewiess A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW.
Eur J Cancer. 2011 Nov;47(16):2387-95

Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Hermann F, von Moos R; SAEDA Investigators Group (Swiss prospective cohort group).
Oncology. 2011;80(1-2):29-33

Randomized, double-blind study of Denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hish V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.
J Clin Oncol. 2011 Mar 20;29(9):1125-32

Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicentre phase IB/II Trial (SAKK 75/06).
Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Mossmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V.
J Clin Oncol. 2011 Feb 20;29(6):626-31

Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomastous testicular germ cell cancer patients.
Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen S, Beyer J, Cathomas R.
Strahlenther Onkol. 2011 Mar;187(3):158-66

Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients.
Cathomas R, Hartmann M, Kreger S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen S; interdisziplinäre Arbeitsgruppe Hodentumore.
Onkologie. 2011;34(1-2):59-64

Proteins in haematology
Clarenbach Re, Mey U.
Ther Umsch. 2011 Nov;68(11):610-7

Diagnosis and treatment of follicular lymphoma.
Hitz F, Ketterer N, Lohri A, Mey U, Pederiva S, Renner C, Taverna C, Hartmann A, Yeow K, Bodis S, Zucca E.
Swiss Med Wkly. 2011 Aug 4;141

Enhancing adherence to Capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U.
Support Care Cancer. 2011 Jul;19(7):1009-18

Factors influencing waiting times for breast cancer care in Switzerland.
Greuter S, Ess MS, Thürlimann B.
Inauguraldissertation, Medizinische Fakultät der Universität Basel
2011

von Moos R, Caspar CB, Steiner R, Angst R, Inauen R, Schmieding K, Thürlimann B.
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Onkologie. 33(8-9): 447-50

Heinzerling LM, Anliker MD, Müller J, Schlaeppi M, von Moos R.
Sarcoidosis induced by interferon-a in melanoma patients: incidence, clinical manifestations, and management strategies.
J Immunother. Oct;33(8): 834-9

von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Oxaliplatin, irinotecan and capecitabine (OCX) for first line treatment of advanced / metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Onkologie. 33(6): 295-9

Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S. Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R.
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02).
Onkologie. 33(5): 222-8

Fehr M, von Moos R, Furrer M, Cathomas R.
Spontaneous pneumothorax during chemotherapy.
Onkologie. 33(10): 527-30

von Moos R, Schaffner R, Cathomas R, Grimm B.
Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication.
J Immunother. Jan; 33(1): 92-5

Padberg B, Frick H, Rost B, Winkler Ch, von Moos R.
Maligne retrorektale Tailgut-Zysten.
Schweiz Med. Forum. 10(26-27): 471-3

Greuter S, von Moos R.
Die antiemetische Prophylaxe bei Chemotherapie. Übersicht und Erläuterung aktueller Guidelines.
Schweizer Zeitschrift für Onkologie. 3

K. Zaman, C. Rochlitz, B. Thürlimann, S. Aebi, R. von Moos, Ch. Mamot, N. Gabriel, L. Rossier-Pansier, R. Stupp, S. Crowe, C. Ruegg.
CePO. MMP-9 as predicitive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK 26/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
Poster presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas; December 2010

D. Koeberle, T. Ruhstaller, L. Jost, O. Pagani, K. Zaman, R. von Moos, C. Oehlschlegel, S. Crowe, C. Pilop, B. Thuerlimann.
Can resistance to Trastuzumab be reversed by endocrine therapy? Combination of Trastuzumab and letrozole after resistance to sequential Trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive, advanced breast cancer: a proof-of-concept trial (SAKK 23/03). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
Poster presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas; December 2010

Stopeck A, Lipton A., Campbell-Baird C, von Moos R, Fan M, Haddock B, Braun A.
Acute-Phase Reactions Following Treatment With Zoledronic Acid or Denosumab: Results From a Randomized, Controlled Phase 3 Study in Patients with Breast Cancer and Bone Metastases.
Poster presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas; December 2010

C.S. Cleeland, D.L. Patrick, L. Fallowfield, R. von Moos, J. Body, B. Egerdie, D. Damyanov, Y. Qian, A. Braun, K. Chung.
Effects of denosumab vs zoledronic acid (ZA) on pain in patients (PTS) with advanced cancer and bone metastases: An integrated analysis of 3 pivotal trials.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010

R. Cathomas, C. Rothermund, R. von Moos, D.C. Betticher, R. Winterhalder, C. Droege, D. Siciliano, D.R. Berthold, M. Pless, S. Gillessen.
Cetuximab in combination with Docetaxel in patients (PTS) with metastatic castration resistant (MCRPC) and docetaxel-refractory prostate cancer: Final analysis of the multicenter phase II trial SAKK 08/07.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010

R. Winterhalder, G. Delmore, P. Hösli, A. Hügli-Dayer, M. Mannhart, F. Otto, S. Pederiva, M. van Lier, S. Nick, R. von Moos.
Impact of different patient management approaches on the control of capecitabine-related adverse events: A prospective cohort analysis from SAEDA II.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010

R. von Moos, G. Delmore, P. Hösli, A. Hügli-Dayer, M. Mannhart, F. Otto, S. Pederiva, M. van Lier, S. Nick, R. Winterhalder.
Initial treatment dose and reasons for dose adjustement during oral capecitabine chemotherapy.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010

M. Pless, D.C. Betticher, M. Buess, R. von Moos, U. Weinberg, E. Kirson, Y. Palti.
A phase II study of tumor treating fields (TTFIELDS) in combination with Pemetrexed for advanced non small cell lung cancer (NSCLC).
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010

B. Thürlimann, C. Rochlitz, S. P. Aebi, U. Güth, R. von Moos, A. Müller, L. U. Von Rohr, M. Baumann, J. B. Huober.
Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

R. Cathomas, C. Rothermundt, R. von Moos, D. C. Betticher, R. C. Winterhalder, C. Droege, D. Siciliano, D. R. Berthold, M. Pless, S. Gillessen.
Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

R. Dummer, O. Michielin, B. Seifert, A. F. Ochsenbein, R. Cathomas, M. R. Schlaeppi, M. Simcock, S. Gillessen, S. M. Goldinger, R. von Moos.
First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

A. F. Ochsenbein, P. Schraml, D. Mihic, M. Simcock, R. Dummer, O. Michielin, B. Seifert, M. R. Schlaeppi, H. Moch, R. von Moos.
MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

G. Fuerstenberger, E. Boneberg, M. Simcock, R. Dummer, S. M. Goldinger, O. Michielin, B. Seifert, A. F. Ochsenbein, M. R. Schlaeppi, R. von Moos.
Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

A. Lipton, A. Stopeck, R. von Moos, D. H. Henry, G. E. Richardson, G. I. Rodriguez, H. P. Bourgeois, C. Ke, S. Jun, R. D. Dansey.
A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

S. Vadhan-Raj, D. H. Henry, R. von Moos, V. Hungria, F. Goldwasser, G. Scagliotti, J. Wang, S. Jun, R. D. Dansey, H. Yeh.
Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

R. von Moos, D. Patrick, L. Fallowfield, C. S. Cleeland, D. H. Henry, Y. Qian, R. D. Dansey, K. Chung.
Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

D. H. Henry, R. von Moos, V. Hungria, L. Costa, P. J. Woll, G. Scogliatti, J. Wang, S. Jun, R. D. Dansey, H. Yeh.
Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.
Journal of Clinical Oncology, 2010: ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)

R. Clemens B. Caspar, R. Steiner, R. Angst, R. Inauen, K. Schmieding, B. Thürlimann.
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Presented at the 2nd IBMS Davos Workshop: Bone Biology & Therapeutics, Davos, Switzerland, 14 – 19 March 2010

Cathomas R.
Therapieoptionen beim fortgeschrittenen Nierenzellkarzinom: update 2010.
Schweizerische Zeitschrift für Onkologie 4/2010, S.19 - 23.

Cathomas R.
Systemische Therapien beim Prostatakarzinom: eine Übersicht.
Facharzt Gynäkologie/Urologie (Österreich) 2010; 4: 14-18

Schmidt F, Cathomas R, Stallmach T, Putora PM, Müller J.
Have you ever heard of hibernoma? A rare but important pitfall in FDG PET/CT.
Nuklearmedizin 2010; 49: N71-73

Strebel R, Gillessen S, Huber U, Morant R, Sulser T, Cathomas R.
Behandlung und interdisziplinäre Zusammenarbeit beim Prostatakarzinom in der Schweiz: Resultate der Swissmove Erhebung.
Presented at SGU Jahrestagung 2010.

Cathomas R, Gillessen S, Huber U, Pless M, Morant R, Winterhalder R, Schmid HP, Sulser T, Strebel R.
Multidisciplinarity in the management of prostate cancer: results of a prospective observational study in Switzerland.
Ann Oncol 2010;21 (Suppl 8):302

Fehr M, von Moos R, Mayer G, Wieland T, Cathomas R.
The influence of cisplatin in porphyrin-metabolism: a pilot study based on a case observation.
Onkologie 2010; 33 (Suppl 6): 77-78

Fresard I, Weinberg U, Kueng M, Cathomas R, Buess M, Pless M, Kirson DE, Betticher DC. J Thorac.
An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer.
Oncol 2010; 5: suppl. 15. Presented at European Lung Cancer Conference (Poster)

Cathomas R, Helbling D, Stenner F, Rothermundt C, Rentsch C, Shahin O, Seifert HH, Zaugg K, Lorch A, Mayer F, Beyer J, De Santis M, Gillessen S.
Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort.
Swiss Med Wkly 2010;140:356-369.

Jungi M, Cathomas R, Rothermundt C.
Radiation Recall Reaction.
Schweiz Med Forum 2010;13:255

Fehr M, Kuhn M, Mayer K, Padberg B, Ulmer U, Cathomas R.
Metastatic angiosarcoma arising from the right atrium: unusual presentation and excellent response to treatment in a young patient.
J Thorac Oncol 2010;5:1301-1302

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R.
Heated (37° C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Supp Cancer Care 2010;18:1263-1270

Fehr M, Kuhn M, Mayer K, Padberg B, Ulmer U, Cathomas R.
Metastatic angiosarcoma arising from the right atrium: oncological options in a rare disease.
Krebsbulletin Schweiz 2010;30:177-180

Mayer D, Cathomas R, Gadient G, Kuhn M.
Atemnot bei Astrozytom, wo ist der Zusammen-hang?
Schweiz Med Forum 2010;10:350-351

P. Keller, A. Angelillo-Scherrer, M. Bargetzi, J. Goede, U. Hess, P. Imbach, Th. Kühne, S. Mach-Pascual, U. Mey, A. Rüfer, A. Schmidt.
Diagnose und Behandlung der primären Immun-Thrombozytopenie.
Schweiz Med Forum 2010;10(50):875–883

Mey UJ.
Current treatment strategies for multiple myeloma.
Ther Umsch. 2010 Oct;67(10):527-35. Review. German

Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U.
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Support Care Cancer. 2010 Jun 16

Taverna C, Bargetzi M, Betticher D, Gmür J, Gregor M, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Renner C.
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Swiss Med Wkly. 2010 Sep 13;140:w13054. Review

Taverna C, Desalmand D, Gmür J, Gregor M, Hess U., Ketterer N, Lerch E, Mey U, Pabst T, Passweg J, Renner Ch, Vögeli J.
Lenalidomid bei vorbehandeltem multiplem Myelom. Leitfaden für die Therapie.
Schweizer Zeitschrift für Onkologie 3/2010

Cathomas R:
Krebs als chronische Krankheit. Erfahrungen und Perspektiven beim Nierenzellkarzinom. The Medical Journal TMJ Schweizer Zeitschrift für Innere Medizin, Nr. 5, 2009, S. 26 – 28.

Cathomas R:
ASCO 2009: Neuigkeiten im Bereich der urogenitalen Tumoren Leading Opinions Hämatologie und Onkologie, Ausgabe 4, 2009, S. 80 – 82.

Cathomas R:
Systemische Therapien beim Prostatakarzinom. Der Mediziner – Facharzt Gynäkolo-gie/Urologie Oesterreich, Ausgabe 3, 2009.

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R:
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer. 2009 Sep 12.

Cathomas R, von Moos R:
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib. Ann Oncol. 2009 Sep; 20(9):1606-7.

Cathomas R, von Rohr A, Hösli P, Giger M, Malz S, Betticher D:
A Swiss retrospective lung cancer survey on dose change and duration of treatment with oral tyrosine kinase inhibitors (TKI). Lung Cancer 2009;64, suppl 1:S55.

Cathomas R, Zbinden S, Dummer R, Gillessen S, Margulies A, Torresan E, Stenner F:
Management der unerwünschten Wirkungen unter Sunitinib. Empfehlungen für die Therapie beim metastasierten Nierenzellkarzinom. Schweizerische Zeitschrift für Onkologie, Ausgabe 3, 2009, S. 24 – 27.

Fehr M, Catschegn S, von Moos R, Reinhart WH:
Einfluss von Bevacizumab (Avastin®) auf die primäre Hämostase (Thrombozyten-aggregation). Schweiz Med Forum 2009, 9: Suppl. 46: 75-76 S.

Fehr M, Kuhn M, Mayer KA, Padberg B, Cathomas R:
Metastatic angiosarcoma arising from the right atrium: unusual presentation and excellent response to treatment in a 36-year-old patient. Swiss Med Wkly 2009;139, suppl 171: 19S.

Fehr M, Madon J, Catschegn S, Asmis L, Reinhart WH, Cathomas R, von Moos R:
Influence of bevacizumab on platelet function in vivo. Ann Oncol 2009.

Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen S, Cathomas R:
Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie 2009;32:586-588.

Hitz F, Martinelli G, Zucca E, von Moos R, Mingrone W, Simcock M, Peterson J, Cogliatti SB, Bertoni F, Zimmermann DR, Ghielmini M:
A multicentre phase Ii trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03 Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Hematol Oncol. 2009 Sep;27(3):154-9.

Klaeser B, Nitzsche E, Schuller JC, Köberle D, Widmer L, Balmer-Majno S, Hany T, Cescato-Wenger C, Brauchli P, Zünd M, Pestalozzi BC, Caspar C, Albrecht S, von Moos R, Ruhstaller T:
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer; results of a prospective multi-center trial (SAKK 75/02) Onkologie. 2009 Dec;32(12):724-30.

Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, Weber E, Grünwald V, Roth A, Leyvraz S:
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009 Sep;45(13):2293-7.

Ribi K, Koeberle D, Schuller JC, Honegger H, Roth A, Hess V, Moosmann P, von Moos R, Borner M, Lombriser N, Pestalozzi B, Ruhstaller T:
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvante chemoradiation? Support Care Cancer. 2009 Feb 7.

Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, Popescu R:
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Swiss Group for Clinical Cancer Research (SAKK) Ann Oncol. 2009 Sep;20(9):1522-8.

Ruhstaller T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thuerlimann B:
Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology. 2009;76(2):142-8.

Schrofer C, Villiger P, Cathomas R:
Metachrones Vierfach-Malignom – zufällige Häufung oder Tumorsyndrom? Praxis 2009;98:1027-1031.

Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH:
Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract (in press) 2009, Jul 17 [E pub ahead of print].

von Moos R, Cathomas R:
Skin problems associated with pegylated liposomal doxo¬rubicin – more than palmoplantar erythrodysesthesia syndrome. Eur J Dermatol 2009;18:566-70 / Eur J Dermatol. 2009 May-Jun;19(3):264-5.

von Moos R, Seifert B, Ochsenbein R, Cathomas R, Schläppi M, Schuller JC, Gillessen S, Michielin O, Goldinger S, Dummer R:
Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). Annal Oncol 2009.

Zenz T, Mohr J, Eldenring E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S:
miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009 Apr 16;113(16):3801-8.

Cathomas R.
Systemische Therapie beim Prostatakarzinom. Schweizerische Zeitschrift für Onkologie, 1/2008: S2-7.

Marc Salzberg, Beat Thürlimann, Ursula Hasler, Geoffrey Delmore, Albert von Rohr, Annatina Thürlimann, Thomas Ruhstaller, Shanna Stopatschinskaja, Roger von Moos
Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Communitiy-Based Observation Study. Oncology. 2007 Dec 17;72(3-4):147-151

Brodmann S, Klaas EG, Cathomas R, Girardi V, von Moos R
Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature. Onkologie. 2007 Dec;30(12):651-4

Cathomas R, Goldhirsch A, von Moos R
Drug-induced immune thrombocytopenia. N Engl J Med. 2007 Nov 1;357(18):1870-1

Ruhstaller T, Thuerlimann B, Koeberle D, von Moos R
Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma ? J Clin Oncol. 2007 Sep 1;25(25):4025-6

Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, Ruhstaller T, Glaus A, Böhme C
Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. Support Care Cancer. 2007 May 26.

Inauen R, Cathomas R, Boehm T, Koeberle D, Pestalozzi BC, Gillessen S, von Moos R
Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology. 2007 Dec 21;72(3-4):209-210

Cathomas R
Onkologie für den Grundversorger - Stand 2007. Schweiz Rundschau Med Prax 2007;96:1989-1995.

Brodmann S, Klaas Gyr E, Cathomas R, Girardi V, von Moos R
Severe Hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature. Onkologie 2007;30:651-654.

Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, Diedrich H, Thomssen H, Mey UJ, Eucker J, Rieder H, Gökbuget N, Hoelzer D, Thiel E
Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica. 2007 Dec;92(12):1699-702

Gorschlüter M, Glasmacher A, Sarazin S, Hackbarth F, Hoebert E, Orlopp K, Schmidt-Wolf IG, Mey UJ
CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: a retrospective study. Leuk Lymphoma. 2007 Mar;48(3):506-12

Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey UJ, Klinkenstein C, Assmann M, von Grünhagen U
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007 May 20;25(15):1986-92

Mey UJ, Maier A, Schmidt-Wolf IG, Ziske C, Forstbauer H, Banat GA, Reber M, Strehl JW, Gorschlueter M
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer. 2007 Jul;15(7):877-84

Mey UJ, Jha V, Strehl JW, Gorschlueter M, Rabe C, Hoebert E, Popp H, Schmidt-Wolf IG
High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. GMS Ger Med Sci 2007; 5:Doc02 (20070619)

R. von Moos und U. Hasler-Strub
Erythropoietin bei onkologischen Patienten - Segen oder Fluch? Leading Opinions Hämatologie & Onkologie. 2007(4):30-3

Fehr M, Lehmann T, Kuhn M
Chylothorax beim Staubsaugen. Schweiz Med Forum 2007; 7:630-2